Tech Briefs

This medical device includes a computer with two screens, a helmet, three software programs, and a recording device for taking eye movement measurements.

As various Parkinsonian disorders involve different brain areas, it is possible to differentiate between them by determining which parameters of eye movements are normal. In this way, the EBT device allows clinicians to rely on a simple set of eye movement parameters to differentiate between very similar syndromes, such as PSP, cortico-basal degeneration (CBD), or multiple system atrophy (MSA).

To identify multiple sclerosis, practitioners will be looking for patients who display a different velocity in the movements of each individual eye, while moving toward a target in a gap test, which is a symptom of damage of the brain’s white matter of the internuclear neurons.

Recently, a new software version of the EBT device has allowed it to help with the diagnosis of multiple sclerosis by confirming eye motricity impairment, which is a sensitive marker for this pathology. It can also be used to help monitor patients' progress and verify the effect of prescribed therapies.

People with multiple sclerosis often suffer from transitory or permanent neuro-ophthalmological problems, with disruptions in eye movements affecting 60 to 80 percent of these patients. The most commonly observed abnormalities are alterations in saccades and pursuits (tracking movements), as well as anomalies in patients’ ability to focus and hold a look.

These tests enable various parameters to be evaluated, including reaction time, eye movement velocity, eye trajectory, and the accuracy of the gaze, as well as cognitive functions such as preparation, activation, or inhibition of the movement. They also allow for a number of parameters to be compared with subjects who display normal eye movements.

The EBT technology is already being used in hospitals to help with the early characterization of Parkinsonian syndromes, to assist in the diagnosis of multiple sclerosis, and to monitor the development of these pathologies. It is also being tested to assess its potential for diagnosing and monitoring patients with dyslexia.

The technology was developed by EyeBrain, Paris, France. For more information about the company and the EyeBrain Tracker, please visit

« Start Prev 1 2 Next End»

The U.S. Government does not endorse any commercial product, process, or activity identified on this web site.